Skip to main content

NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Schedule of DCTD Presentations at the 2026 American Association for Cancer Research Annual Meeting

DCTD-supported research will be presented at the AACR Annual Meeting from April 17-22, 2026 in San Diego, California. The following tables contain oral and poster presentations with DCTD staff speakers and co-authors.

Oral Presentations

Date/Time	*Title/DCTD Speaker**	ID
April 18 10:51 AM - 11:01 AM	Safety of Prolonged Checkpoint Inhibitor Exposure in Alveolar Soft Part Sarcoma (ASPS) Patients *Alice P. Chen, MD, Nancy Moore, RN, Jared Foster, PhD, Christina Rosenberger, PhD, James H. Doroshow, MD	CT004
April 19 2:30 PM - 3:30 PM	NCI Drug Development Resources and Grant Writing Strategies for New and Early-Stage Investigators Rosemarie Aurigemma, PhD, Christophe Marchand, PhD, Sundar Venkatachalam, PhD, Morgan O’Hayre, PhD, *Yali Fu, PhD	NIH02
April 21 2:30 PM - 3:30 PM	NCI/NIH Opportunities in Funding: NCI-Cancer Diagnosis Program Initiatives and Biospecimen Resources for Investigators Aniruddha Ganguly, PhD, Lokesh Agrawal, PhD, *Ana I. Robles, PhD	NIH09

Poster Presentations

Date/Time	Title/DCTD Presenter (If Applicable)	ID
April 20 2:00 PM - 5:00 PM	Interleukin-1 upregulates dual oxidase 2 expression and ROS production in human pancreatic cancer cells in a STAT1/STAT3-dependent manner	2881/21
	IL-1 beta/ IL-6 co-stimulation synergistically mediates DUOX2/DUOXA2 complex up-regulation via JAK/STAT and p38 signaling events	3319/26
April 21 9:00 AM - 12:00 PM	HDAC inhibitors induce NOX5 expression in human uveal melanoma cells in a Brd4-Sp1/Sp3-dependent manner Smitha Antony, PhD	4491/10
	Advancing new rational drug combinations to treat mutant KRAS-driven pancreatic adenocarcinoma	4473/21
April 21 2:00 PM - 5:00 PM	Heat shock protein inhibitors suppress cytokine-induced DUOX2 mRNA and protein expression in human pancreatic cancer cells in a JAK, STAT dependent manner	6578/11
	DUOX2 is finely tuned by synergism between cytokines IL-6, IL-22, IL-17A, and TNFα in colon cancer	6585/18
	Pilot study of pidnarulex pharmacodynamics in patients with advanced solid tumors Jibran Ahmed, MD	CT293/27
	Development of pancreatic and colon patient-derived xenograft (PDX) tumor microarrays (TMAs) from the NCI patient derived models repository	6061/7
	Rapid analysis and response evaluation of combination anti-neoplastic agents in rare tumors (RARE CANCER) trial (RARE 3): Tiragolumab + Atezolizumab	CT259/24
	HPV+ and HPV- head and neck cancer patient-derived models in the NCI Patient-Derived Models Repository	6067/13
April 22 9:00 AM - 12:00 PM	Synergistic cytotoxicity through combination of DNA methyltransferase (DNMT) inhibitors in cancer cells	7067/14

Meet-the-Expert Presentations

Date/Time	Topic	Presenter
April 20 1:30 PM - 2:00 PM	Early-Stage Investigator Policy & R37 Extension Process	Aniruddha Ganguly, PhD Cancer Diagnosis Program
April 21 10:30 AM - 11:00 AM	DCTD’s Investigative Toxicology Laboratory: Early and Late-Stage Drug Development	Elizabeth Glaze, PhD Developmental Therapeutics Program
April 21 1:30 PM - 2:00 PM	NCI Integrative Medicine Cancer Therapeutics Portfolio and Funding Opportunities-Lifestyle Modification and Microbiome	Dani Xi, PhD Office Of Cancer Complementary and Alternative Medicine